Transplantation for chronic myelogenous leukemia: Yes, no, maybe so...an Oregon perspective

Richard Maziarz, Michael J. Mauro

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder in which allogeneic stem cell transplantation remains the only curative option, but its use is limited by donor availability and treatment-related morbidity and mortality. Imatinib mesylate is a targeted agent for CML with efficacy to date, which is superior to all other nontransplant therapy and has limited toxicity. The curative potential of imatinib remains to be proven and may be limited to a small number of patients. Optimal decision making regarding the use of these divergent therapies has not been defined. This paper reviews critical data relevant to these treatment options and provides an approach to current management of the CML patient.

Original languageEnglish (US)
Pages (from-to)459-469
Number of pages11
JournalBone Marrow Transplantation
Volume32
Issue number5
DOIs
StatePublished - Sep 2003

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transplantation
Stem Cell Transplantation
Therapeutics
Hematopoietic Stem Cells
Decision Making
Tissue Donors
Morbidity
Mortality
Imatinib Mesylate

Keywords

  • Allogeneic stem cell transplatation
  • Chronic myelogenous leukemia
  • Imatinib mesylate

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Transplantation for chronic myelogenous leukemia : Yes, no, maybe so...an Oregon perspective. / Maziarz, Richard; Mauro, Michael J.

In: Bone Marrow Transplantation, Vol. 32, No. 5, 09.2003, p. 459-469.

Research output: Contribution to journalArticle

@article{5d9ed9dd855a4d8caccf151c4f4186ba,
title = "Transplantation for chronic myelogenous leukemia: Yes, no, maybe so...an Oregon perspective",
abstract = "Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder in which allogeneic stem cell transplantation remains the only curative option, but its use is limited by donor availability and treatment-related morbidity and mortality. Imatinib mesylate is a targeted agent for CML with efficacy to date, which is superior to all other nontransplant therapy and has limited toxicity. The curative potential of imatinib remains to be proven and may be limited to a small number of patients. Optimal decision making regarding the use of these divergent therapies has not been defined. This paper reviews critical data relevant to these treatment options and provides an approach to current management of the CML patient.",
keywords = "Allogeneic stem cell transplatation, Chronic myelogenous leukemia, Imatinib mesylate",
author = "Richard Maziarz and Mauro, {Michael J.}",
year = "2003",
month = "9",
doi = "10.1038/sj.bmt.1704163",
language = "English (US)",
volume = "32",
pages = "459--469",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Transplantation for chronic myelogenous leukemia

T2 - Yes, no, maybe so...an Oregon perspective

AU - Maziarz, Richard

AU - Mauro, Michael J.

PY - 2003/9

Y1 - 2003/9

N2 - Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder in which allogeneic stem cell transplantation remains the only curative option, but its use is limited by donor availability and treatment-related morbidity and mortality. Imatinib mesylate is a targeted agent for CML with efficacy to date, which is superior to all other nontransplant therapy and has limited toxicity. The curative potential of imatinib remains to be proven and may be limited to a small number of patients. Optimal decision making regarding the use of these divergent therapies has not been defined. This paper reviews critical data relevant to these treatment options and provides an approach to current management of the CML patient.

AB - Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder in which allogeneic stem cell transplantation remains the only curative option, but its use is limited by donor availability and treatment-related morbidity and mortality. Imatinib mesylate is a targeted agent for CML with efficacy to date, which is superior to all other nontransplant therapy and has limited toxicity. The curative potential of imatinib remains to be proven and may be limited to a small number of patients. Optimal decision making regarding the use of these divergent therapies has not been defined. This paper reviews critical data relevant to these treatment options and provides an approach to current management of the CML patient.

KW - Allogeneic stem cell transplatation

KW - Chronic myelogenous leukemia

KW - Imatinib mesylate

UR - http://www.scopus.com/inward/record.url?scp=0141478769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141478769&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704163

DO - 10.1038/sj.bmt.1704163

M3 - Article

C2 - 12942091

AN - SCOPUS:0141478769

VL - 32

SP - 459

EP - 469

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -